Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment

被引：13
作者：
Gevaert, Thomas [1 ,2 ]
Montironi, Rodolfo [3 ]
Lopez-Beltran, Antonio [4 ,5 ]
Van Leenders, Geert [6 ]
Allory, Yves [7 ]
De Ridder, Dirk [8 ]
Claessens, Frank [9 ]
Kockx, Mark [10 ]
Akand, Murat [11 ]
Joniau, Steven [8 ]
Netto, George [12 ]
Libbrecht, Louis [13 ]
机构：
[1] Katholieke Univ Leuven, Lab Expt Urol, Organ Syst, Leuven, Belgium
[2] AZ Klina, Dept Pathol, Brasschaat, Belgium
[3] Polytech Univ Marche Reg, United Hosp, Sch Med, Sect Pathol Anat, Ancona, Italy
[4] Fac Med, Dept Surg & Pathol, Anat Pathol Unit, Cordoba, Spain
[5] Champalimaud Clin Ctr, Lisbon, Portugal
[6] Erasmus Univ, Med Ctr, Dept Pathol, Rotterdam, Netherlands
[7] Univ Paris Est Creteil Val de Marne UPEC, Hop Henri Mondor, Fac Med, Serv Anat Pathol, Creteil, France
[8] Univ Hosp Leuven, Dept Urol, Leuven, Belgium
[9] Katholieke Univ Leuven, Dept Cellular & Mol Med, Mol Endocrinol Lab, Leuven, Belgium
[10] HistoGeneX, Dept Mol Pathol, Antwerp, Belgium
[11] Selcuk Univ, Sch Med, Dept Urol, Konya, Turkey
[12] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[13] Univ Clin St Luc, Dept Pathol, Sint Lambrechts Woluwe, Belgium
来源：
SEMINARS IN CANCER BIOLOGY | 2018年 / 52卷
关键词：
Immunotherapy; Bladder; Kidney; Prostate; Biomarkers; RENAL-CELL CARCINOMA; RESISTANT PROSTATE-CANCER; MISMATCH REPAIR GENES; METASTATIC UROTHELIAL CARCINOMA; INVASIVE BLADDER-CANCER; UPPER URINARY-TRACT; IMMUNE CHECKPOINT INHIBITORS; CISPLATIN-BASED CHEMOTHERAPY; LYNCH SYNDROME; ANDROGEN RECEPTOR;
D O I：
10.1016/j.semcancer.2017.10.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with genito-urinary (GU) cancers at different stages of disease. Robust and reliable biomarkers are crucial for an appropriate inclusion of patients in clinical trials and for a reliable patient selection for treatments with immunomodulatory drugs. The increasing knowledge on the genomic landscape of GU cancers supports stratification of patients for targeted therapies. This review focusses on emerging biomarkers and the role of genomics in predicting clinical benefit to immunomodulatory agents in GU cancers. Based on cancer incidences and available data we restricted this overview to bladder, prostate and renal cancer.
引用
收藏
页码：216 / 227
页数：12
相关论文
共 177 条
  • [61] PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
    Gevensleben, Heidrun
    Holmes, Emily Eva
    Goltz, Diane
    Dietrich, Joern
    Sailer, Verena
    Ellinger, Joerg
    Dietrich, Dimo
    Kristiansen, Glen
    [J]. ONCOTARGET, 2016, 7 (48) : 79943 - 79955
  • [62] The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
    Gevensleben, Heidrun
    Dietrich, Dimo
    Golletz, Carsten
    Steiner, Susanne
    Jung, Maria
    Thiesler, Thore
    Majores, Michael
    Stein, Johannes
    Uhl, Barbara
    Mueller, Stefan
    Ellinger, Joerg
    Stephan, Carsten
    Jung, Klaus
    Brossart, Peter
    Kristiansen, Glen
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (08) : 1969 - 1977
  • [63] Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma
    Ghatalia, Pooja
    Zibelman, Matthew
    Geynisman, Daniel M.
    Plimack, Elizabeth R.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (01)
  • [64] Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium
    Goebell, Peter J.
    Knowles, Margaret A.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (04) : 409 - 428
  • [65] Financial toxicity in cancer careEdging toward solutions
    Goldstein, Daniel A.
    [J]. CANCER, 2017, 123 (08) : 1301 - 1302
  • [66] Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
    Goltz, Diane
    Gevensleben, Heidrun
    Dietrich, Joern
    Ellinger, Joerg
    Landsberg, Jennifer
    Kristiansen, Glen
    Dietrich, Dimo
    [J]. ONCOIMMUNOLOGY, 2016, 5 (10):
  • [67] Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
    Graff, Julie N.
    Alumkal, Joshi J.
    Drake, Charles G.
    Thomas, George V.
    Redmond, William L.
    Farhad, Mohammad
    Cetnar, Jeremy P.
    Ey, Frederick S.
    Bergan, Raymond C.
    Slottke, Rachel
    Beer, Tomasz M.
    [J]. ONCOTARGET, 2016, 7 (33) : 52810 - 52817
  • [68] Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
    Gubin, Matthew M.
    Zhang, Xiuli
    Schuster, Heiko
    Caron, Etienne
    Ward, Jeffrey P.
    Noguchi, Takuro
    Ivanova, Yulia
    Hundal, Jasreet
    Arthur, Cora D.
    Krebber, Willem-Jan
    Mulder, Gwenn E.
    Toebes, Mireille
    Vesely, Matthew D.
    Lam, Samuel S. K.
    Korman, Alan J.
    Allison, James P.
    Freeman, Gordon J.
    Sharpe, Arlene H.
    Pearce, Erika L.
    Schumacher, Ton N.
    Aebersold, Ruedi
    Rammensee, Hans-Georg
    Melief, Cornelis J. M.
    Mardis, Elaine R.
    Gillanders, William E.
    Artyomov, Maxim N.
    Schreiber, Robert D.
    [J]. NATURE, 2014, 515 (7528) : 577 - +
  • [69] Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
    Gulley, James L.
    Arlen, Philip M.
    Madan, Ravi A.
    Tsang, Kwong-Yok
    Pazdur, Mary P.
    Skarupa, Lisa
    Jones, Jacquin L.
    Poole, Diane J.
    Higgins, Jack P.
    Hodge, James W.
    Cereda, Vittore
    Vergati, Matteo
    Steinberg, Seth M.
    Halabi, Susan
    Jones, Elizabeth
    Chen, Clara
    Parnes, Howard
    Wright, John J.
    Dahut, William L.
    Schlom, Jeffrey
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (05) : 663 - 674
  • [70] The evolutionary history of lethal metastatic prostate cancer
    Gundem, Gunes
    Van Loo, Peter
    Kremeyer, Barbara
    Alexandrov, Ludmil B.
    Tubio, Jose M. C.
    Papaemmanuil, Elli
    Brewer, Daniel S.
    Kallio, Heini M. L.
    Hoegnas, Gunilla
    Annala, Matti
    Kivinummi, Kati
    Goody, Victoria
    Latimer, Calli
    O'Meara, Sarah
    Dawson, Kevin J.
    Isaacs, William
    Emmert-Buck, Michael R.
    Nykter, Matti
    Foster, Christopher
    Kote-Jarai, Zsofia
    Easton, Douglas
    Whitaker, Hayley C.
    Neal, David E.
    Cooper, Colin S.
    Eeles, Rosalind A.
    Visakorpi, Tapio
    Campbell, Peter J.
    McDermott, Ultan
    Wedge, David C.
    Bova, G. Steven
    [J]. NATURE, 2015, 520 (7547) : 353 - +
234567891011